Jasper Therapeutics Investors Face Lead Plaintiff Deadline in Securities Class Action

Overview

• Notices from multiple investor firms highlight a November 18, 2025 deadline to seek lead plaintiff status in the case against Jasper Therapeutics.
• The putative class period runs from November 30, 2023 through July 3, 2025, and the class has not been certified.
• The complaint contends the company lacked adequate oversight of third‑party manufacturers, risking cGMP noncompliance and overstating clinical and financial prospects.
• Jasper’s July 7, 2025 press release reported BEACON dose cohorts were confounded by a single drug‑product lot also used in ETESIAN, and announced program halts, a pause in asthma work, a SCID halt, and cost‑cutting including a potential restructuring.
• Following that disclosure, JSPR shares fell 55.1% to close at $3.04 on July 7, 2025.